Kazia Therapeutics Ltd (NAS:KZIA)
$ 5.86 -0.54 (-8.44%) Market Cap: 19.51 Mil Enterprise Value: 17.37 Mil PE Ratio: 0 PB Ratio: 4.37 GF Score: 41/100

Kazia Therapeutics Ltd at LD Micro Main Event Transcript

Dec 14, 2020 / 09:00PM GMT
Unidentified Participant

Hello, everyone. Hi, we are live, this is Tanya. I am hosting this seminar with Kazia Therapeutics. I have Dr. James Garner with me today. Kazia Therapeutics is an innovative -- excuse me, is an Australian biotech company focused on brain cancer. James, go ahead and take the stage.

James Garner
Kazia Therapeutics Limited - MD, CEO

Tanya, thank you. Ladies and gentlemen, good afternoon. It's a great pleasure to be here. This is our first time presenting at the LD Micro Main Event. And it really caps off very nicely what has been an extraordinary year for Kazia.

And I want to spend the next few minutes just introducing our company and then be really pleased to take some Q&A. But I think all of the key points that I really want to make about the company are, as shown here on this slide.

And I think the first thing to say is we have a really first-class asset that we're developing here in Kazia. It's a drug called paxalisib. It was originally developed by Genentech. Of course, the company well known to folks on this call.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot